Celldex Therapeutics, Inc earnings per share and revenue
On Nov 10, 2025, CLDX reported earnings of -1.01 USD per share (EPS) for Q3 25, missing the estimate of -0.91 USD, resulting in a -9.94% surprise. Revenue reached --, compared to an expected 1.01 million, with a -100.00% difference. The market reacted with a +7.50% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 analysts forecast an EPS of -1.02 USD, with revenue projected to reach 1.51 million USD, implying an increase of 0.99% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
FAQ
What were Celldex Therapeutics, Inc's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Celldex Therapeutics, Inc reported EPS of -$1.01, missing estimates by -9.94%, and revenue of $0.00, -100% below expectations.
How did the market react to Celldex Therapeutics, Inc's Q3 2025 earnings?
The stock price moved up 7.5%, changed from $22.67 before the earnings release to $24.37 the day after.
When is Celldex Therapeutics, Inc expected to report next?
The next earning report is scheduled for Feb 25, 2026.
What are the forecasts for Celldex Therapeutics, Inc's next earnings report?
Based on 17
analysts, Celldex Therapeutics, Inc is expected to report EPS of -$1.02 and revenue of $1.51M for Q4 2025.